Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.52 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | ITGB3 | P05106 | 3/20 | 0.45 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.45 |
| ▸ | ANPEP | P15144 | 1/20 | 0.44 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | NSD2 | O96028 | 1/20 | 0.43 |
| ▸ | GRK2 | P25098 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL845174 | 0.82 | AKR1B1 (0.48) | CA2AKR1B1LMNAGAATSHR | |
| SCHEMBL16050000 | 0.82 | AKR1B1 (0.71) | CA2CAMK2AAKR1B1LMNAGAA | |
| SCHEMBL16050220 | 0.82 | AKR1B1 (0.71) | CA2CAMK2AAKR1B1LMNAGAA | |
| SCHEMBL2852457 | 0.80 | ALDH1A1 (0.50) | CA2GAATSHRPTGS1ANPEP | |
| SCHEMBL9285426 | 0.80 | MAOB (0.48) | CA2TSHRALDH1A1TDP1 | |
| SCHEMBL3115195 | 0.79 | CA2 (0.60) | CA2CAMK2AAKR1B1LMNAGAA | |
| SCHEMBL69614 | 0.78 | CA2 (0.79) | CA2CAMK2AAKR1B1LMNAGAA | |
| SCHEMBL6295521 | 0.76 | PAM (0.56) | CA2CAMK2AAKR1B1LMNAGAA | |
| SCHEMBL6295520 | 0.76 | PAM (0.56) | CA2CAMK2AAKR1B1LMNAGAA | |
| SCHEMBL8984192 | 0.75 | CA2 (0.56) | CA2CAMK2AAKR1B1LMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 226 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2582715-B1 | GROWTH HORMONE SECRETATOGUE RECEPTOR ANTAGONISTS AND USES THEREOF | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2018-11-28 | — | — | EP | claimed |
| US-9724381-B2 | Methods of inhibiting the ghrelin/growth hormone secretatogue receptor pathway and uses thereof | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2017-08-08 | — | — | US | claimed |
| US-9315546-B2 | Growth hormone secretatogue receptor antagonists and uses thereof | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2016-04-19 | — | — | US | claimed |
| WO-2013142229-A1 | DESIGNING NOVEL PEPTIDES FOR INDUCING FIBRONECTIN MATRIX ASSEMBLY | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2013-09-26 | — | — | WO | claimed |
| US-20130172242-A1 | GROWTH HORMONE SECRETATOGUE RECEPTOR ANTAGONISTS AND USES THEREOF | MCGILL UNIVERSITY (CA) | 2013-07-04 | — | — | US | claimed |
| EP-2582715-A2 | GROWTH HORMONE SECRETATOGUE RECEPTOR ANTAGONISTS AND USES THEREOF | The Administrators of the Tulane Educational Fund (US) | 2013-04-24 | — | — | EP | claimed |
| WO-2011159917-A2 | GROWTH HORMONE SECRETATOGUE RECEPTOR ANTAGONISTS AND USES THEREOF | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2011-12-22 | — | — | WO | claimed |
| WO-2011126882-A2 | THERAPEUTIC PEPTIDES AND THEIR DERIVATIVES AND THERAPEUTIC USES THEREOF | AMERICAN TYPE CULTURE COLLECTION (US) | 2011-10-13 | — | — | WO | claimed |
| WO-2010132580-A2 | METHODS OF INHIBITING THE GHRELIN/GROWTH HORMONE SECRETATOGUE RECEPTOR PATHWAY AND USES THEREOF | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2010-11-18 | — | — | WO | claimed |
| WO-2024137362-A1 | GENERATION OF ALVEOLAR EPITHELIAL TYPE 1 (AT1) CELLS | TRUSTEES OF BOSTON UNIVERSITY (US) | 2024-06-27 | — | — | WO | disclosed |
| WO-2024112749-A1 | METHODS OF TREATING HEART FAILURE | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2024-05-30 | — | — | WO | disclosed |
| WO-2024107916-A1 | METHODS AND COMPOSITION RELATING TO PARTICLE CAPTURE | TRUSTEES OF BOSTON UNIVERSITY (US) | 2024-05-23 | — | — | WO | disclosed |
| US-20240124542-A1 | GDF11 VARIANTS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2024-04-18 | — | — | US | disclosed |
| US-20240117033-A1 | METHODS AND COMPOSITIONS RELATING TO ANTI-MFSD2A ANTIBODIES | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2024-04-11 | — | — | US | disclosed |
| US-20120135918-A1 | METHODS OF INHIBITING THE GHRELIN/GROWTH HORMONE SECRETATOGUE RECEPTOR PATHWAY AND USES THEREOF | MCGILL UNIVERSITY (CA) | 2012-05-31 | — | — | US | disclosed |
| WO-2012058201-A2 | METHOD FOR DETERMINING ACTIVATORS OF EXCITATORY SYNAPSE FORMATION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-05-03 | — | — | WO | disclosed |
| WO-2011159917-A2 | GROWTH HORMONE SECRETATOGUE RECEPTOR ANTAGONISTS AND USES THEREOF | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2011-12-22 | — | — | WO | disclosed |
| US-20110268736-A1 | METHOD FOR TREATING CONGENITAL MYOPATHY | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2011-11-03 | — | — | US | disclosed |
| WO-2011126882-A2 | THERAPEUTIC PEPTIDES AND THEIR DERIVATIVES AND THERAPEUTIC USES THEREOF | AMERICAN TYPE CULTURE COLLECTION (US) | 2011-10-13 | — | — | WO | disclosed |
| WO-2010132580-A2 | METHODS OF INHIBITING THE GHRELIN/GROWTH HORMONE SECRETATOGUE RECEPTOR PATHWAY AND USES THEREOF | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2010-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120135918-A1 | METHODS OF INHIBITING THE GHRELIN/GROWTH HORMONE SECRETATOGUE RECEPTOR PATHWAY AND USES THEREOF | GHSR, GIPR, GHRHR | CA2 1150/4885CAMK2A 1388/4885AKR1B1 561/4885 |
| US-20130172242-A1 | GROWTH HORMONE SECRETATOGUE RECEPTOR ANTAGONISTS AND USES THEREOF | GHSR, GHRHR, GIPR | CA2 4513/4885CAMK2A 1110/4885AKR1B1 1756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.